“This allows CB21 Pharma to bring to the pharmaceutical markets both synthesized and isolated Cannabidiol APIs through exclusive distribution and brokerage arrangements with CBDepot”, says Dr. Jan Storch the CEO of CB21 Pharma.

During the CPhI 2017 event in Frankfurt, CBDepot introduced as the first company in the EU isolated GMP CBD via 3rd party contract manufacturer from Prague. Since summer 2019 the group took on a project of relocation of Cannabidiol manufacture to new premises in Brno.

“We are extremely excited our pharma-specific team managed to deliver the regulatory approval pretty much within deadline leaving aside the quarantine measures which have caused three months delay in the auditing process. Next two big steps are submitting Active Substance Master File and implementation of decarboxylation and distillation processes which will also allow us to provide full-spectrum APIs for various pharmaceutical uses”, says Boris Baňas, the CSO of CBDepot.